Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin

Retrophin logoRetrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RTRX
  • CUSIP:
Key Metrics:
  • Previous Close: $16.98
  • 50 Day Moving Average: $17.97
  • 200 Day Moving Average: $16.12
  • Trailing P/E Ratio: 6.90
  • Foreward P/E Ratio: -22.05
  • P/E Growth: 9.46
  • Market Cap: $623.69M
  • Outstanding Shares: 36,731,000
  • Beta: 1.08
Additional Links:
Companies Related to Retrophin:

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.67 (62.94% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
DateFirmActionRatingPrice TargetDetails
8/8/2016BMO Capital MarketsReiterated RatingOutperform$25.00 -> $28.00View Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/27/2016Leerink SwannReiterated RatingBuy$27.00View Rating Details
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00View Rating Details
5/23/2015NomuraReiterated RatingBuy$31.00 -> $34.00View Rating Details
5/15/2015Avondale PartnersInitiated CoverageOutperform$39.00View Rating Details
(Data available from 8/24/2014 forward)


Earnings History for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q2($0.23)$0.07$32.73 million$33.30 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.40 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)ViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Retrophin (NASDAQ:RTRX)
Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)


Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Retrophin (NASDAQ:RTRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline logoWhat Will Retrophin Inc (NASDAQ:RTRX) Get For Its Money On A Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Deal? (NASDAQ:RTRX) - August 19 at 7:04 PM
News IconTakeover Rumors Around Raptor Pharmaceutical (RPTP); Bullish View On Digital Ally (DGLY) (NASDAQ:RTRX) - August 18 at 7:29 PM logoRaptor Pharmaceutical : Retrophin Reportedly Considers Bid For Raptor Pharma (NASDAQ:RTRX) - August 18 at 10:14 AM logoRetrophin Reportedly Considers Bid For Raptor Pharma (NASDAQ:RTRX) - August 18 at 10:14 AM logoRETROPHIN, INC. Financials (NASDAQ:RTRX) - August 16 at 7:19 PM logoRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:RTRX) - August 15 at 7:36 PM logo8:33 am Retrophin appoints Neil McFarlane as COO (NASDAQ:RTRX) - August 15 at 9:24 AM logoRetrophin Appoints Neil McFarlane Chief Operating Officer (NASDAQ:RTRX) - August 15 at 9:24 AM logoNotable Thursday Option Activity: AGEN, TWTR, RTRX (NASDAQ:RTRX) - August 11 at 7:44 PM logoETF’s with exposure to Retrophin, Inc. : August 11, 2016 (NASDAQ:RTRX) - August 11 at 7:44 PM logoRetrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : August 11, 2016 (NASDAQ:RTRX) - August 11 at 10:31 AM logoRetrophin, Inc. :RTRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:RTRX) - August 10 at 7:44 PM logoRetrophin Inc. (RTRX) is Trading Higher on Unusual Volume for August 01 - (NASDAQ:RTRX) - August 4 at 7:41 PM logoRetrophin reports 2Q loss (NASDAQ:RTRX) - August 4 at 7:41 PM logoQ2 2016 Retrophin Inc Earnings Release - After Market Close (NASDAQ:RTRX) - August 4 at 10:27 AM logoNoteworthy Wednesday Option Activity: RUBI, RTRX, SCTY (NASDAQ:RTRX) - July 22 at 7:01 PM
News IconRetrophin Incorporated (NASDAQ:RTRX) Shorted Shares Increased By 4.68% - Consumer Eagle (NASDAQ:RTRX) - July 22 at 10:08 AM logoRetrophin to Report Second Quarter 2016 Financial Results (NASDAQ:RTRX) - July 21 at 4:30 PM logoRetrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : July 21, 2016 (NASDAQ:RTRX) - July 21 at 8:13 AM logoRetrophin (RTRX) Adds New Board member - (NASDAQ:RTRX) - July 20 at 8:05 PM
News IconIncreased Stock Volatility Watch: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily (NASDAQ:RTRX) - July 20 at 8:05 PM logoRETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:RTRX) - July 20 at 6:03 AM logoRetrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors (NASDAQ:RTRX) - July 19 at 4:30 PM
News IconShare Performance Summary for: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph (NASDAQ:RTRX) - July 19 at 8:20 AM
News IconShares Lower on the Year Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph (NASDAQ:RTRX) - July 19 at 8:20 AM
News IconShares Experiencing a Downtrend: Retrophin, Inc. (NASDAQ:RTRX) - TGP (NASDAQ:RTRX) - July 17 at 6:36 PM logoEven Under 'Worst Case Scenario,' BMO Thinks Retrophin Should Trade Higher (NASDAQ:RTRX) - July 16 at 10:27 AM logoEx-drug exec Shkreli's U.S. fraud trial set for June 2017 (NASDAQ:RTRX) - July 16 at 10:27 AM logoRetrophin, Inc. (NasdaqGM:RTRX) Fundamental Star Rating Report - CML News (NASDAQ:RTRX) - July 15 at 6:12 PM
News IconShkreli gets a year to figure out how to throw his ex-lawyer under the bus - Ars Technica (NASDAQ:RTRX) - July 14 at 8:06 PM logoEven Under 'Worst Case Scenario,' BMO Thinks Retrophin Should Trade Higher - Benzinga (NASDAQ:RTRX) - July 14 at 7:30 PM logoDid Shkreli kill the biotech rally? (NASDAQ:RTRX) - July 14 at 5:24 PM logoEx-drug executive Shkreli to face U.S. fraud trial in June 2017 (NASDAQ:RTRX) - July 14 at 4:35 PM logoAccused fraudster Martin Shkreli's trial set for June 26 (NASDAQ:RTRX) - July 14 at 2:24 PM
News IconStock Providing Gains on the Month for Investors: Retrophin, Inc. (NASDAQ:RTRX) - Telanagana Press (NASDAQ:RTRX) - July 13 at 10:07 AM logoThe GOP Needs To Tackle The High Price Of Prescription Drugs (NASDAQ:RTRX) - July 13 at 12:01 AM logoRetrophin Inc. (RTRX): Scopia Capital Adds To Its Stake - Insider Monkey (blog) (NASDAQ:RTRX) - July 12 at 7:28 PM
News IconRetrophin Inc. (RTRX): Scopia Capital Adds To Its Stake (NASDAQ:RTRX) - July 12 at 1:55 PM logoRetrophin Inc Realized Volatility Hits Extreme Level - CML News (NASDAQ:RTRX) - July 11 at 7:07 PM
News IconStock Performance Rundown on: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph (NASDAQ:RTRX) - July 11 at 7:07 PM
News IconRetrophin Inc (NASDAQ:RTRX) Institutional Investors Quarterly Sentiment - Press Telegraph (NASDAQ:RTRX) - July 11 at 7:07 PM logoNext Weeks Broker Price Targets For Retrophin, Inc. (RTRX) - Fiscal Standard (NASDAQ:RTRX) - July 10 at 6:29 PM logoRetrophin, Inc. (RTRX) Current Analyst Ratings - Fiscal Standard (NASDAQ:RTRX) - July 8 at 7:13 PM
News IconShort Information Review for: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily (NASDAQ:RTRX) - July 7 at 7:17 PM logoNew Broker Ratings For Retrophin, Inc. (RTRX) - FTSE News (NASDAQ:RTRX) - July 7 at 7:17 PM logoThis Weeks Broker Price Targets For Retrophin, Inc. (RTRX) - Fiscal Standard (NASDAQ:RTRX) - July 4 at 6:21 PM
News IconShare Performance Recap for: Retrophin, Inc. (NASDAQ:RTRX) - Press Telegraph (NASDAQ:RTRX) - July 4 at 6:21 PM
News IconRetrophin Incorporated (NASDAQ:RTRX) Short Interest Decreased By 2.66% - Engelwood Daily (NASDAQ:RTRX) - July 2 at 6:45 PM
News IconShort Data Recap for: Retrophin, Inc. (NASDAQ:RTRX) - Engelwood Daily (NASDAQ:RTRX) - June 30 at 10:02 AM logoRetrophin, Inc. (RTRX) Updated Price Targets - FTSE News (NASDAQ:RTRX) - June 30 at 10:02 AM


Retrophin (NASDAQ:RTRX) Chart for Wednesday, August, 24, 2016

Last Updated on 8/24/2016 by Staff